|
LA JOLLA PHARMACEUTICAL TO PRESENT
AT LEHMAN BROTHERS CONFERENCE
SAN DIEGO, March 3, 2003 -- La Jolla
Pharmaceutical Company (Nasdaq: LJPC)
announced today that Steven B. Engle,
Chairman and CEO, will give a presentation
on Tuesday, March 4, 2003 at 3:45 p.m.
Eastern Time at the Lehman Brothers
Sixth Annual Global Healthcare Conference
at the Loews Miami Beach Hotel in Miami
Beach, Florida. An audio webcast of
the presentation will be available through
the Company's Web site http://www.ljpc.com.
La Jolla Pharmaceutical Company is
a biotechnology company developing therapeutics
for antibody-mediated autoimmune diseases
afflicting several million people in
the United States and Europe. The Company
is developing Riquent™ for the
treatment of lupus kidney disease, a
leading cause of sickness and death
in patients with lupus. The Company
is also developing LJP 1082 for the
treatment of antibody-mediated thrombosis,
a condition in which patients suffer
from recurrent stroke, deep-vein thrombosis
and other thrombotic events. The Company's
common stock is traded on The Nasdaq
Stock Market under the symbol LJPC.
For more information about the Company,
visit our Web site: http://www.ljpc.com.
Except for historical statements, this
press release contains forward-looking
statements involving significant risks
and uncertainties, and a number of factors,
both foreseen and unforeseen, could
cause actual results to differ materially
from our current expectations. Forward-looking
statements include those, which express
a plan, belief, expectation, estimation,
anticipation, intent, contingency, future
development or similar expression. Although
we expect to meet with the U.S. Food
and Drug Administration ("FDA")
to discuss the results of our Phase
III trial of RiquentTM, there is no
guarantee that a meeting with the FDA
can be held in a timely manner, or at
all, or that our meetings with them
will result in us being able to continue
to develop RiquentTM. Our analyses of
clinical results of Riquent™, previously
known as LJP 394, our drug candidate
for the treatment of systemic lupus
erythematosus ("lupus"), and
LJP 1082, our drug candidate for the
treatment of antibody-mediated thrombosis
("thrombosis"), are ongoing
and could result in a finding that these
drug candidates are not effective in
large patient populations, do not provide
a meaningful clinical benefit or may
reveal a potential safety issue requiring
us to develop new candidates. Our blood
test to measure the binding affinity
for Riquent™ is experimental, has
not been validated by independent laboratories,
may require regulatory approval, and
may be necessary for the approval and
the commercialization of Riquent™.
Our other potential drug candidates
are at earlier stages of development
and involve comparable risks. Analysis
of our clinical trials could have negative
or inconclusive results. Any positive
results observed to date may not be
indicative of future results. In any
event, the FDA may require additional
clinical trials, or may not approve
our drugs. Our ability to develop and
sell our products in the future may
be affected by the intellectual property
rights of third parties. Additional
risk factors include the uncertainty
of: obtaining required regulatory approvals,
including delays associated with any
approvals that we may obtain; FDA approval
of our manufacturing facilities and
processes; the increase in capacity
of our manufacturing capabilities for
possible commercialization; successfully
marketing and selling our products;
our lack of manufacturing, marketing,
and sales experience; generating future
revenue from product sales or other
sources such as collaborative relationships;
future profitability; our need for additional
financing; and our dependence on patents
and other proprietary rights. Readers
are cautioned to not place undue reliance
upon forward-looking statements, which
speak only as of the date hereof, and
we undertake no obligation to update
forward-looking statements to reflect
events or circumstances occurring after
the date hereof. Interested parties
are urged to review the risks described
in our Registration Statement on Form
S-3, filed December 10, 2002, our Annual
Report on Form 10-K for the year ended
December 31, 2001, and in other reports
and registration statements that we
file with the Securities and Exchange
Commission from time to time.
Terms
of Use & Privacy Policy
Copyright © 2008, La Jolla Pharmaceutical Company
|